Ulcerative Colitis news | Breaking ulcerative colitis news | Ulcerative Colitis

Coach gets her life back

...Cold turkey.

No more basketball, a sport that had shaped her life since childhood.But Francis was wrong about quitting being the hardest part.

Her journey was just beginning, something that would force her to deal with her toughest opponent - her soul."I know it sounds horrible, but I lost myself in this business, I became something I never wanted to be," Francis, 40, said.

"I was destroying myself, literally.

If we lost a game, it was the end of the world.

I thought it was the end of my life, what would people think of me?

Winning and being successful was so my identity."I was afraid I was a failure in other people's eyes."Pressure is offAfter three years of intensive professional therapy, prayer, and coming to terms with her own fears, Francis is again whole.The digestive problems are gone, and Francis has taken a bold step - she's back to coaching OU's women's team."Now my perspective and mindset has changed, and that takes a lot of the pressure off of me," Francis said.

"I had to change.

I am more secure in myself.

And that is probably the biggest thing.

I am more confident, if I lose or have to deal with some questions or pressure, I won't question myself or destroy myself in the process."Francis has now gone through a half-season, and is still healthy.

The

Shire seeks European approval for ulcerative colitis drug

...Advertisement If approved, SPD476 would offer a once-daily mesalazine treatment for the disorder.

Last year, the mesalazine market segment for "The European submissions for SPD476 represent the achievement of another important milestone for Shire," said Shire chief executive Matthew Emmens.

"Currently there is no once-daily oral treatment for

Cambridge Antibody Technology Group plc Announces First Quarter ...

... In January 2006, Abbott stated that these follow-on indications represent a US$1-2 billion incremental peak year "sales opportunity" beyond the base RA business.

CAT Product Candidates CAT-354 is a fully human anti-IL13 monoclonal antibody being developed by CAT, initially as a treatment for severe asthma.

Following the completion in 2005 of a Phase I clinical trial, CAT has recently received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to commence a repeat-dose safety study of CAT-354 in patients with mild/moderate asthma.

The trial, which will take place in the UK, will commence in the first quarter of calendar year 2006 and will study safety, tolerability and pharmacokinetics.

The development of CAT-3888 and CAT-8015, immunotoxins which are potential treatments for a number of B-cell malignancies, continues as planned.

GC-1008 is a pan-specific fully human anti-TGF(beta) monoclonal antibody being developed by CAT and Genzyme.

The companies anticipate that an IND application for a Phase I clinical trial in oncology indications will be filed in the first quarter of calendar year 2006.

The strategic alliance with AstraZeneca continues its excellent progress, with six active discovery programmes.

Other Licensed Product Candidates ABT-874 is a fully human anti-IL-12 monoclonal antibody, isolated and optimised by CAT in collaboration with Abbott and licensed to Abbott.

Abbott continues to develop ABT...

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news

Health and Fitness   Health Living